Drug
Intravenous immunoglobulins (IVIG)
Intravenous immunoglobulins (IVIG) is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 2 completed trials
Completion Rate
100%(2/2)
Active Trials
1(33%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_4
1
33%
Ph early_phase_1
1
33%
Ph phase_3
1
33%
Phase Distribution
1
Early Stage
0
Mid Stage
2
Late Stage
Phase Distribution3 total trials
Early Phase 1First-in-human
1(33.3%)
Phase 3Large-scale testing
1(33.3%)
Phase 4Post-market surveillance
1(33.3%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
100.0%
2 of 2 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Completed(2)
Detailed Status
Completed2
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
100.0%
Most Advanced
Phase 4
Trials by Phase
Early Phase 11 (33.3%)
Phase 31 (33.3%)
Phase 41 (33.3%)
Trials by Status
completed267%
recruiting133%
Recent Activity
1 active trials
Showing 3 of 3
recruitingphase_3
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
NCT06533098
completedphase_4
Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.
NCT04222023
completedearly_phase_1
Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients
NCT00176059
Clinical Trials (3)
Showing 3 of 3 trials
NCT06533098Phase 3
A Study of Nipocalimab or Intravenous Immunoglobulin (IVIG) in Pregnancies At Risk of Fetal and Neonatal Alloimmune Thrombocytopenia (FNAIT)
NCT04222023Phase 4
Intravenous Immunoglobulins for Prevention of BKV Infection in Kidney Transplant Recipients According to BKV Genotype-specific Neutralizing Antibody Titers at the Day of Transplantation.
NCT00176059Early Phase 1
Immunoregulatory Effects of Immunoglobulin Induction Therapy in Renal Transplant Recipients
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3